These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 25459221

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
    Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS.
    Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
    [Abstract] [Full Text] [Related]

  • 3. Colistin and polymyxin B in critical care.
    Michalopoulos A, Falagas ME.
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z, Danziger L.
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [Abstract] [Full Text] [Related]

  • 6. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A, Kasiakou SK, Tam VH, Falagas ME.
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [Abstract] [Full Text] [Related]

  • 7. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD, Suresh K.
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J.
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [Abstract] [Full Text] [Related]

  • 9. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
    Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A.
    Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
    [Abstract] [Full Text] [Related]

  • 10. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T, Dai C, Ciccotosto GD, Cappai R, Hoyer D, Li J.
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [Abstract] [Full Text] [Related]

  • 11. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A, Izanloo A, Rastegar M.
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [Abstract] [Full Text] [Related]

  • 12. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z, Jain R, Danziger LH.
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [Abstract] [Full Text] [Related]

  • 13. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME, Feola DJ, Rapp RP.
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [Abstract] [Full Text] [Related]

  • 14. Colistin and polymyxin B: peas in a pod, or chalk and cheese?
    Nation RL, Velkov T, Li J.
    Clin Infect Dis; 2014 Jul 01; 59(1):88-94. PubMed ID: 24700659
    [Abstract] [Full Text] [Related]

  • 15. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
    Gales AC, Reis AO, Jones RN.
    J Clin Microbiol; 2001 Jan 01; 39(1):183-90. PubMed ID: 11136768
    [Abstract] [Full Text] [Related]

  • 16. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ, Falagas ME.
    Int J Antimicrob Agents; 2017 Feb 01; 49(2):233-238. PubMed ID: 27686609
    [Abstract] [Full Text] [Related]

  • 17. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM, Levin AS, De Pedri EH, Fung L, Rossi F, Duboc G, Barone AA, Costa SF.
    Ann Clin Microbiol Antimicrob; 2007 Aug 15; 6():8. PubMed ID: 17697363
    [Abstract] [Full Text] [Related]

  • 18. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS, Karatza DC.
    Expert Rev Anti Infect Ther; 2010 Sep 15; 8(9):1009-17. PubMed ID: 20818945
    [Abstract] [Full Text] [Related]

  • 19. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).
    Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA, Ambrose PG.
    Antimicrob Agents Chemother; 2020 Jan 27; 64(2):. PubMed ID: 31767718
    [Abstract] [Full Text] [Related]

  • 20. Polymyxin Resistance Mechanisms: From Intrinsic Resistance to Mcr Genes.
    Meletis G, Skoura L.
    Recent Pat Antiinfect Drug Discov; 2018 Jan 27; 13(3):198-206. PubMed ID: 30474535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.